Your browser is too old
We can't provide a great video experience on old browserUpdate now
Acid Peptic Disease and Antacids
In this lecture ´´Drugs Used in Acid Peptic Diseases´´ are explained. Section one is about ´´Acid Peptic Disease and Antacids´´. In the beginning, educator gives an overview of acid peptic diseases. Then Agents that reduce intragastric acidity are classified and discussed. Following this physiology of acid secretion is elaborated. After that antacids are explained. Subsequently, their mechanism of action is illustrated. Lastly, discussion continues on ADRs.
H2 Receptor Antagonist and Proton Pump Inhibitors
Section two is about ‘’H2 Receptor Antagonist and Proton Pump Inhibitors’’. At first, H2 receptor antagonists are discussed. After that their chemistry and pharmacokinetics is pursued. Then clinical comparisons of H2-receptor blockers are carried out. Likewise, clinical use is explained. Following this, gastroesophageal reflux disease (GERD) comes under consideration. Moving onward, peptic ulcer disease is pursued. Next focus is on nonnuclear dyspepsia. Then information is delivered about prevention of bleeding from stress-related gastritis. This is followed by explanation of adverse effects and contraindications respectively. Afterwards, proton pump inhibitors are elucidated. Furthermore, their mechanism of action, chemistry and pharmacokinetics are pursued. Additionally, clinical uses are reported. Then adverse effects are highlighted. Finally, educator reveals information about drug interaction.
Mucosal Protective Agents
Section three is about ‘’Mucosal Protective Agents’’. Educator begins with the elucidation of mechanism of action. Then information about sucralfate is given. Following this, clinical use and ADRs are pursued. After that prostaglandin compounds are discussed. Subsequently, bismuth compounds are elaborated. In the end, ADRs are reported.
Pancreatic Enzyme Supplements
Section four is about ‘’Pancreatic Enzyme Supplements’’. Earlier in this section exocrine pancreatic insufficiency is explained. Then pancreatin is discussed. This is followed by elucidation of pancrelipase. After that its pharmacokinetics and pharmacodynamics are pursued. Last part of discussion of this section is ADRs.
Bile Acid Agents
Section five is about ‘’Bile Acid Agents’’. Educator starts this section by explaining urasidol. Its pharmacokinetics, pharmacodynamics, clinical use and adverse drug reactions are pursued later on in succession. Subsequently, obeticholic acid is the next subject of discussion. then mechanism of action is exhibited. Lastly, Obeticholic Acid ADRs are highlighted.